Lionco Pharm Grp Co Ltd (603669) — Net Asset Quality Index
Lionco Pharm Grp Co Ltd (603669) has a Net Asset Quality Index of 55.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.12 Billion minus total liabilities of CN¥498.43 Million yields net assets of CN¥623.24 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of Lionco Pharm Grp Co Ltd for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Lionco Pharm Grp Co Ltd Net Asset Quality Index Over Time (2011–2025)
This chart shows how Lionco Pharm Grp Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 55.6%, representing net assets of CN¥623.24 Million against total assets of CN¥1.12 Billion CNY. For live market cap and overall valuation, see 603669 stock market capitalisation.
Annual Net Asset Quality Index for Lionco Pharm Grp Co Ltd (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Lionco Pharm Grp Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Lionco Pharm Grp Co Ltd (603669) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 56.0% | CN¥620.28 Million | CN¥1.11 Billion | CN¥486.50 Million | ▼ -5.3 pp |
| 2024 | 61.3% | CN¥769.76 Million | CN¥1.26 Billion | CN¥485.57 Million | ▲ +4.0 pp |
| 2023 | 57.3% | CN¥931.04 Million | CN¥1.62 Billion | CN¥693.52 Million | ▼ -3.9 pp |
| 2022 | 61.2% | CN¥1.14 Billion | CN¥1.86 Billion | CN¥720.32 Million | ▲ +3.2 pp |
| 2021 | 58.0% | CN¥1.46 Billion | CN¥2.51 Billion | CN¥1.06 Billion | ▲ +3.5 pp |
| 2020 | 54.5% | CN¥1.48 Billion | CN¥2.72 Billion | CN¥1.24 Billion | ▼ -14.2 pp |
| 2019 | 68.7% | CN¥1.31 Billion | CN¥1.91 Billion | CN¥599.60 Million | ▲ +2.0 pp |
| 2018 | 66.6% | CN¥1.38 Billion | CN¥2.07 Billion | CN¥689.97 Million | ▼ -12.0 pp |
| 2017 | 78.7% | CN¥1.30 Billion | CN¥1.65 Billion | CN¥352.40 Million | ▼ -8.3 pp |
| 2016 | 87.0% | CN¥1.17 Billion | CN¥1.34 Billion | CN¥174.57 Million | ▲ +3.7 pp |
| 2015 | 83.3% | CN¥1.12 Billion | CN¥1.34 Billion | CN¥223.98 Million | ▲ +16.5 pp |
| 2014 | 66.8% | CN¥374.13 Million | CN¥559.83 Million | CN¥185.70 Million | ▲ +6.5 pp |
| 2013 | 60.3% | CN¥351.02 Million | CN¥582.12 Million | CN¥231.09 Million | ▼ -4.4 pp |
| 2012 | 64.7% | CN¥236.22 Million | CN¥364.89 Million | CN¥128.67 Million | ▲ +12.1 pp |
| 2011 | 52.6% | CN¥128.55 Million | CN¥244.38 Million | CN¥115.83 Million | — |